{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:41:43Z","timestamp":1791650503983,"version":"4.3.4"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,27]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Thyroid eye disease (TED) is a disabling, organ-specific autoimmune disease that is a global health concern. Recently, certain biological agents have demonstrated unique advantages for the treatment of TED. Teprotumumab is an emerging biological agent used for TED treatment. This study assessed whether teprotumumab can serve as an effective and safe treatment for active TED through a meta-analysis of the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched 4 databases (PubMed, The Cochrane Library, Web of Science, and Embase) for randomized controlled trials regarding the treatment of Graves\u2019 ophthalmopathy by teprotumumab by March 31, 2024. We screened the literature library and extracted the data according to the inclusion and exclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our study included 5 articles that involved 411 cases. Significant differences were reported in the change from baseline in proptosis (proptosis vs baseline), diplopia response at week 24, and clinical activity score of 0 or 1 at week 24 in the teprotumumab versus placebo group. The teprotumumab group reported no significant risk of adverse events or serious adverse events during the intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Teprotumumab significantly decreased proptosis and clinical activity score and improved diplopia response in patients with TED, with fewer adverse effects. Therefore, it is a promising biological agent. However, this conclusion should be further validated by high-quality, long-term randomized controlled trials with large sample sizes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000042966","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T15:00:39Z","timestamp":1751295639000},"page":"e42966","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Teprotumumab for treating active thyroid eye disease: A meta-analysis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1975-7954","authenticated-orcid":false,"given":"Xiangguo","family":"Cong","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Sunshine Union Hospital, Weifang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shandong Zibo Central Hospital, Zibo, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260813","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/2576117X.2021.1991182","article-title":"Thyroid-associated orbitopathy: management and treatment.","volume":"72","author":"Hennein","year":"2022","journal-title":"J Binocul Vis Ocul Motil"},{"key":"R2-20260813","doi-asserted-by":"crossref","first-page":"109436","DOI":"10.1016\/j.exer.2023.109436","article-title":"Development and application of animal models to study thyroid-associated ophthalmopathy.","volume":"230","author":"Shen","year":"2023","journal-title":"Exp Eye Res"},{"key":"R3-20260813","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/IOP.0000000000002555","article-title":"Dysthyroid optic neuropathy.","volume":"39","author":"Potvin","year":"2023","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R4-20260813","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","article-title":"Pathogenesis of thyroid eye disease: review and update on molecular mechanisms.","volume":"100","author":"Khong","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R5-20260813","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy.","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"R6-20260813","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves\u2019 orbitopathy.","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"key":"R7-20260813","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41587-020-0481-8","article-title":"IGF-1R drugs travel from cancer cradle to Graves\u2019.","volume":"38","author":"Dolgin","year":"2020","journal-title":"Nat Biotechnol"},{"key":"R8-20260813","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s10792-021-01706-3","article-title":"Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.","volume":"41","author":"Ali","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R9-20260813","doi-asserted-by":"crossref","first-page":"16969","DOI":"10.3390\/ijms242316969","article-title":"Role of the insulin-like growth factor (IGF) axis in diseases.","volume":"24","author":"Perks","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R10-20260813","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association.","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"key":"R11-20260813","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy.","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"R12-20260813","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease.","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"R13-20260813","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/bjophthalmol-2020-318314","article-title":"Improvement of asymmetric thyroid eye disease with teprotumumab.","volume":"106","author":"Ugradar","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R14-20260813","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R15-20260813","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41433-021-01539-5","article-title":"Teprotumumab for thyroid eye disease: early response is not required for benefit.","volume":"36","author":"Ugradar","year":"2022","journal-title":"Eye (London, England)"},{"key":"R16-20260813","doi-asserted-by":"crossref","first-page":"615993","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, natural history, risk factors, and prevention of graves\u2019 orbitopathy.","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol"},{"key":"R17-20260813","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2169\/internalmedicine.53.1518","article-title":"Graves\u2019 ophthalmopathy: epidemiology and natural history.","volume":"53","author":"Hiromatsu","year":"2014","journal-title":"Int Med (Tokyo, Japan)"},{"key":"R18-20260813","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1210\/endrev\/bnae018","article-title":"Teprotumumab for the treatment of thyroid eye disease.","volume":"45","author":"Ugradar","year":"2024","journal-title":"Endocr Rev"},{"key":"R19-20260813","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ncl.2010.03.010","article-title":"Thyroid eye disease.","volume":"28","author":"Cockerham","year":"2010","journal-title":"Neurol Clin"},{"key":"R20-20260813","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1177\/11206721231199367","article-title":"Imaging of dysthyroid optic neuropathy.","volume":"34","author":"Rana","year":"2024","journal-title":"Eur J Ophthalmol"},{"key":"R21-20260813","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ceo.13899","article-title":"Thyroid eye disease: redefining its management\u2014a review.","volume":"49","author":"Jain","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"key":"R22-20260813","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/s-0035-1555762","article-title":"Current insights into the pathogenesis of graves\u2019 ophthalmopathy.","volume":"47","author":"Bahn","year":"2015","journal-title":"Hormone Metab Res = Hormon- und Stoffwechselforschung = Hormones et metabolisme"},{"key":"R23-20260813","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations.","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R24-20260813","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13044-019-0074-0","article-title":"Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves\u2019 orbitopathy.","volume":"12","author":"Walasik-Szempli\u0144ska","year":"2019","journal-title":"Thyroid Res"},{"key":"R25-20260813","doi-asserted-by":"crossref","first-page":"116","DOI":"10.17116\/oftalma2021137041116","article-title":"Monoclonal antibodies in the treatment of thyroid eye disease.","volume":"137","author":"Cheredanova","year":"2021","journal-title":"Vestn Oftalmol"},{"key":"R26-20260813","doi-asserted-by":"crossref","first-page":"111035","DOI":"10.1016\/j.mce.2020.111035","article-title":"Disorders of IGFs and IGF-1R signaling pathways.","volume":"518","author":"Forbes","year":"2020","journal-title":"Mol Cell Endocrinol"},{"key":"R27-20260813","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41433-020-01297-w","article-title":"Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.","volume":"35","author":"Ugradar","year":"2021","journal-title":"Eye (London, England)"},{"key":"R28-20260813","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1089\/thy.2007.0404","article-title":"Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy.","volume":"18","author":"Smith","year":"2008","journal-title":"Thyroid"},{"key":"R29-20260813","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.","volume":"181","author":"Douglas","year":"2008","journal-title":"J Immunol"},{"key":"R30-20260813","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/WCO.0000000000000894","article-title":"Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment.","volume":"34","author":"Johnson","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"R31-20260813","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-i receptor and thyroid-associated ophthalmopathy.","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"key":"R32-20260813","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/imj.15067","article-title":"Medical and surgical treatment of thyroid eye disease.","volume":"52","author":"Hall","year":"2022","journal-title":"Intern Med J"},{"key":"R33-20260813","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity.","volume":"109","author":"Douglas","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"R34-20260813","first-page":"612","article-title":"Thyroid-associated ophthalmopathy in Iranian patients.","volume":"49","author":"Kashkouli","year":"2011","journal-title":"Acta Med Iran"},{"key":"R35-20260813","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial.","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R36-20260813","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study.","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R37-20260813","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","article-title":"Teprotumumab for the treatment of chronic thyroid eye disease.","volume":"36","author":"Ugradar","year":"2022","journal-title":"Eye (London, England)"},{"key":"R38-20260813","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1097\/IOP.0000000000001831","article-title":"Teprotumumab for dysthyroid optic neuropathy: early response to therapy.","volume":"37","author":"Sears","year":"2021","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R39-20260813","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1097\/WNO.0000000000001298","article-title":"Visual recovery of dysthyroid optic neuropathy with teprotumumab.","volume":"42","author":"Lopez","year":"2022","journal-title":"J Neuro-ophthalmol"},{"key":"R40-20260813","doi-asserted-by":"crossref","first-page":"101111","DOI":"10.1016\/j.ajoc.2021.101111","article-title":"Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: a multicenter study.","volume":"23","author":"Sears","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R41-20260813","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","article-title":"Hearing dysfunction after treatment with teprotumumab for thyroid eye disease.","volume":"240","author":"Sears","year":"2022","journal-title":"Am J Ophthalmol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:01:43Z","timestamp":1786633303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":41,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042966","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}